Our study demonstrates that Pt(iv) derivative of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)2(PhB)2Cl2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(iv) derivatives of cisplatin with either two hydroxido, two acetato or two valproato ligands. The high potency of this compound (and some others) is due to several factors including enhanced internalization, probably driven by "synergistic accumulation" of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity. ctc-[Pt(NH3)2(PhB)2Cl2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB. Mechanistically, ctc-[Pt(NH3)2(PhB)2Cl2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway. Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)2(PhB)2Cl2] may not depend of p53. Pt(iv) derivatives of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs. ctc-[Pt(NH3)2(PhB)2Cl2] is significantly more potent than its valproate analog ctc-[Pt(NH3)2(VPA)2Cl2]. These compounds combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.

Department of Biophysics Faculty of Science Palacky University 17 listopadu 12 CZ 77146 Olomouc Czech Republic

Dipartimento di Scienze del Farmaco Universita di Padova Via Marzolo 5 35131 Padova Italy Email

Institute for Drug Research School of Pharmacy The Hebrew University Jerusalem 91120 Israel

Institute of Biophysics Academy of Sciences of the Czech Republic v v i Kralovopolska 135 CZ 61265 Brno Czech Republic

Zobrazit více v PubMed

Zhang J., Liu D., Li Y., Sun J., Wang L., Zang A. Mini-Rev. Med. Chem. 2009;9:1357–1366. PubMed

Wheate N. J., Walker S., Craig G. E., Oun R. Dalton Trans. 2010;39:8113–8127. PubMed

Quiroga A. G. Curr. Top. Med. Chem. 2011;11:2613–2622. PubMed

Ardizzoni A., Antonelli G., Grossi F., Tixi L., Cafferata M., Rosso R. Ann. Oncol. 1999;10(suppl. 5):S13–S17. PubMed

Belani C. P. Semin. Oncol. 2002;29:4–9. PubMed

Itoyama Y., Kochi M., Yamashiro S., Yoshizato K., Kuratsu J., Ushio Y. Neurol. Med. Chir. 1993;33:28–31. PubMed

Diyabalanage H. V., Granda M. L., Hooker J. M. Cancer Lett. 2013;329:1–8. PubMed PMC

Huang W. J., Tang Y. A., Chen M. Y., Wang Y. J., Hu F. H., Wang T. W., Chao S. W., Chiu H. W., Yeh Y. L., Chang H. Y., Juan H. F., Lin P., Wang Y. C. Cancer Lett. 2014;346:84–93. PubMed

Jin K. L., Park J. Y., Noh E. J., Hoe K. L., Lee J. H., Kim J. H., Nam J. H. J. Gynecol. Oncol. 2010;21:262–268. PubMed PMC

Atadja P. W. Prog. Drug Res. 2011;67:175–195. PubMed

Lee M. J., Kim Y. S., Kummar S., Giaccone G., Trepel J. B. Curr. Opin. Oncol. 2008;20:639–649. PubMed PMC

Mann B. S., Johnson J. R., Cohen M. H., Justice R., Pazdur R. Oncologist. 2007;12:1247–1252. PubMed

Kelland L. R. Drug Resist. Updates. 2000;3:139–141. PubMed

Fuertes M. A., Castilla J., Alonso C., Perez J. M. Curr. Med. Chem. 2003;10:257–266. PubMed

Wang D., Lippard S. J. Nat. Rev. Drug Discovery. 2005;4:307–320. PubMed

Griffith D., Morgan M. P., Marmion C. J. Chem. Commun. 2009:6735–6737. PubMed

Griffith D. M., Duff B., Suponitsky K. Y., Kavanagh K., Morgan M. P., Egan D., Marmion C. J. J. Inorg. Biochem. 2011;105:793–799. PubMed

Brabec V., Griffith D. M., Kisova A., Kostrhunova H., Zerzankova L., Marmion C. J., Kasparkova J. Mol. Pharm. 2012;9:1990–1999. PubMed

Giandomenico C. M., Abrams M. J., Murrer B. A., Vollano J. F., Rheinheimer M. I., Wyer S. B., Bossard G. E., Higgins J. D. Inorg. Chem. 1995;34:1015–1021. PubMed

Hall M. D., Hambley T. W. Coord. Chem. Rev. 2002;232:49–67.

Chin C. F., Wong D. Y., Jothibasu R., Ang W. H. Curr. Top. Med. Chem. 2011;11:2602–2612. PubMed

Wexselblatt E., Gibson D. J. Inorg. Biochem. 2012;117:220–229. PubMed

Yang J., Sun X., Mao W., Sui M., Tang J., Shen Y. Mol. Pharm. 2012;9:2793–2800. PubMed

Alessio M., Zanellato I., Bonarrigo I., Gabano E., Ravera M., Osella D. J. Inorg. Biochem. 2013;129:52–57. PubMed

Novohradsky V., Zerzankova L., Stepankova J., Vrana O., Raveendran R., Gibson D., Kasparkova J., Brabec V. J. Inorg. Biochem. 2014;140:72–79. PubMed

Novohradsky V., Zerzankova L., Stepankova J., Vrana O., Raveendran R., Gibson D., Kasparkova J., Brabec V. Biochem. Pharmacol. 2015;95:133–144. PubMed

Wilson J. J., Lippard S. J. Chem. Rev. 2014;114:4470–4495. PubMed PMC

Zhang J. Z., Bonnitcha P., Wexselblatt E., Klein A. V., Najajreh Y., Gibson D., Hambley T. W. Chem.–Eur. J. 2013;19:1672–1676. PubMed

Najajreh Y., Khazanov E., Jawbry S., Ardeli-Tzaraf Y., Perez J. M., Kasparkova J., Brabec V., Barenholz Y., Gibson D. J. Med. Chem. 2006;49:4665–4673. PubMed

Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Proc. Natl. Acad. Sci. U. S. A. 2001;98:87–92. PubMed PMC

Riedl S. J., Salvesen G. S. Nat. Rev. Mol. Cell Biol. 2007;8:405–413. PubMed

Caserta T. M., Smith A. N., Gultice A. D., Reedy M. A., Brown T. L. Apoptosis. 2003;8:345–352. PubMed

Witzig T. E., Timm M., Stenson M., Svingen P. A., Kaufmann S. H. Clin. Cancer Res. 2000;6:681–692. PubMed

Gillies L. A., Kuwana T. J. Cell. Biochem. 2014;115:632–640. PubMed

Kalimutho M., Minutolo A., Grelli S., Federici G., Bernardini S. Acta Pharmacol. Sin. 2011;32:1387–1396. PubMed PMC

Pichler V., Heffeter P., Valiahdi S. M., Kowol C. R., Egger A., Berger W., Jakupec M. A., Galanski M., Keppler B. K. J. Med. Chem. 2012;55:11052–11061. PubMed PMC

Amaral J. D., Xavier J. M., Steer C. J., Rodrigues C. M. Discov. Med. 2010;9:145–152. PubMed

Chin C. F., Tian Q., Setyawati M. I., Fang W., Tan E. S., Leong D. T., Ang W. H. J. Med. Chem. 2012;55:7571–7582. PubMed

Pracharova J., Saltarella T., Radosova Muchova T., Scintilla S., Novohradsky V., Novakova O., Intini F. P., Pacifico C., Natile G., Ilik P., Brabec V., Kasparkova J. J. Med. Chem. 2015;58:847–859. PubMed

O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N., Friend S., Fornace Jr A. J., Kohn K. W. Cancer Res. 1997;57:4285–4300. PubMed

Wang D., Lippard S. J. Nat. Rev. Drug Discovery. 2005;4:307–320. PubMed

Oldfield S. P., Hall M. D., Platts J. A. J. Med. Chem. 2007;50:5227–5237. PubMed

Ravera M., Gabano E., Zanellato I., Bonarrigo I., Alessio M., Arnesano F., Galliani A., Natile G., Osella D. J. Inorg. Biochem. 2015;150:1–8. PubMed

Gabano E., Ravera M., Colangelo D., Osella D. Curr. Chem. Biol. 2007;1:278–289.

Tarasenko N., Cutts S. M., Phillips D. R., Berkovitch-Luria G., Bardugo-Nissim E., Weitman M., Nudelman A., Rephaeli A. Biochem. Pharmacol. 2014;88:158–168. PubMed

Fass D. M., Shah R., Ghosh B., Hennig K., Norton S., Zhao W. N., Reis S. A., Klein P. S., Mazitschek R., Maglathlin R. L., Lewis T. A., Haggarty S. J. ACS Med. Chem. Lett. 2011;2:39–42. PubMed PMC

Soussi T., Beroud C. Nat. Rev. Cancer. 2001;1:233–240. PubMed

Wade M., Li Y. C., Wahl G. M. Nat. Rev. Cancer. 2013;13:83–96. PubMed PMC

Pineau T., Hudgins W. R., Liu L., Chen L. C., Sher T., Gonzalez F. J., Samid D. Biochem. Pharmacol. 1996;52:659–667. PubMed

Marshall C. J. Science. 1993;259:1865–1866. PubMed

Samid D., Ram Z., Hudgins W. R., Shack S., Liu L., Walbridge S., Oldfield E. H., Myers C. E. Cancer Res. 1994;54:891–895. PubMed

Hudgins W. R., Shack S., Myers C. E., Samid D. Biochem. Pharmacol. 1995;50:1273–1279. PubMed

Burkitt K., Ljungman M. Mol. Cancer. 2008;7:24. PubMed PMC

Kaiser G. S., Germann S. M., Westergaard T., Lisby M. Mutat. Res. 2011;713:64–75. PubMed

Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand

Half-Sandwich Ru(II) Halogenido, Valproato and 4-Phenylbutyrato Complexes Containing 2,2'-Dipyridylamine: Synthesis, Characterization, Solution Chemistry and In Vitro Cytotoxicity